The agreement includes potential performance-based windfalls, with RedHill eligible for up to $35 million in additional payments tied to worldwide net sales milestones. This sale marks a decisive shift for the firm, which is looking to shed legacy assets to fund an aggressive expansion of its commercial franchise. Apotex, having already secured the remaining 30% stake in the drug through its acquisition of Cumberland Pharmaceuticals' branded business, now holds full control over the treatment for H. pylori infection.
In section Releases
RedHill Biopharma Divests Talicia to Apotex in $18 Million Deal
RedHill Biopharma has offloaded its 70% interest in Talicia to Apotex Health Corp. for an initial $18 million in cash. The transaction provides the Raleigh-based company with immediate liquidity as it looks to pivot its commercial strategy toward new, higher-value gastrointestinal product opportunities and long-term operational profitability.
Dror Ben-Asher, CEO of RedHill, noted that the capital injection is essential for scaling the company's existing GI portfolio. While the firm continues to advance a pipeline that includes treatments for inflammatory and infectious diseases, the divestment signals a clear intent to prioritize high-growth assets over established, shared-ownership stakes.
Comments (0)
No comments yet. Be the first!